AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19050653 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Resistance Training (MRT)
Number of subjects: 84
Study 19050653 — intervention group
Group type: COMPARATOR
Intervention: Weight Resistance Training (WRT)
Number of subjects: 84
Study 17098140 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography
Number of subjects: 54
Study 17098140 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography adjusted to lean body mass
Number of subjects: 54
Study 17098140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 54
Study 15258475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' reports
Number of subjects: 179
Study 15258475 — intervention group
Group type: EXPERIMENTAL
Intervention: Providers' reports
Number of subjects: 179
Study 14733417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (AA) 200 mg 3 times/week
Number of subjects: 27
Study 14733417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose desferroxamine (DFO) 1 mg/Kg/week
Number of subjects: 27
Study 14733417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 10836600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided air-enema reduction
Number of subjects: 199
Study 10836600 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided air reduction
Number of subjects: 199
Study 9168506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive three-step protocol consisting of colistin inhalations and oral ciprofloxacin.
Number of subjects: 91
Study 9168506 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic controls).
Number of subjects: 91
Study 9168506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment (intensive protocol).
Number of subjects: 91
Study 9168506 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients who developed chronic PA infection.
Number of subjects: 91
Study 9168506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment with colistin inhalation and oral ciprofloxacin for 3 months.
Number of subjects: 91
Study 1541782 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide tooth whitening products
Number of subjects: 0
Study 1541782 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent
Number of subjects: 0
Study 3541428 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell vaccine
Number of subjects: 0
Study 3541428 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Vero rabies vaccine
Number of subjects: 0
Study 3541428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal bovine kidney cell vaccine
Number of subjects: 0
Study 3541428 — intervention group
Group type: COMPARATOR
Intervention: HDCV (commercial human diploid cell vaccine)
Number of subjects: 0
Study 3541428 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-1-1 postexposure regimen (all vaccines)
Number of subjects: 0
Study 28439774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) albumin infusion (n=100)
Number of subjects: 189
Study 28439774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) albumin infusion within 2 hours of onset
Number of subjects: 189
Study 28439774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=89)
Number of subjects: 189
Study 26821621 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 18144
Study 24582900 — intervention group
Group type: EXPERIMENTAL
Intervention: Handball training
Number of subjects: 60
Study 24582900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22814302 — intervention group
Group type: EXPERIMENTAL
Intervention: Integuseal (cyanoacrylate microbial sealant)
Number of subjects: 56
Study 22814302 — intervention group
Group type: COMPARATOR
Intervention: Not using Integuseal (control group)
Number of subjects: 56
Study 21176630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher Select stent
Number of subjects: 228
Study 21176630 — intervention group
Group type: COMPARATOR
Intervention: Excel stent
Number of subjects: 228
Study 18250260 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 20
Study 18250260 — intervention group
Group type: COMPARATOR
Intervention: Nocebo
Number of subjects: 20
Study 16402634 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 (10 mg/day)
Number of subjects: 34
Study 16402634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (5-HT(1A) agonist)
Number of subjects: 0
Study 12562581 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 12562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone
Number of subjects: 0
Study 10357321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (5.4 mmol)
Number of subjects: 39
Study 10357321 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 39
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric preconditioning at 50 daPa/s
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric preconditioning at 100 daPa/s
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric preconditioning at 200 daPa/s
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric preconditioning at 400 daPa/s
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: All rates of tympanometric preconditioning
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance tympanic membranes
Number of subjects: 103
Study 8951447 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 tympanometries
Number of subjects: 103
Study 1756347 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-anxiety drug
Number of subjects: 144
Study 1756347 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 144
Study 1756347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 1756347 — intervention group
Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 144
Study 6800536 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 1037
Study 6800536 — intervention group
Group type: COMPARATOR
Intervention: Barium radiography
Number of subjects: 1037
Study 30727980 — intervention group
Group type: EXPERIMENTAL
Intervention: RGB-02
Number of subjects: 239
Study 30727980 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim (Neulasta®)
Number of subjects: 239
Study 28846688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy Outreach Worker (POW) intervention
Number of subjects: 486
Study 28846688 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 486
Study 26475420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (DEX) 5 mg/d
Number of subjects: 26
Study 26475420 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (intravenous normal saline)
Number of subjects: 26
Study 26475420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DEX and placebo treatments
Number of subjects: 26
Study 26475420 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of spontaneous nystagmus (SPN)
Number of subjects: 26
Study 23244565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with spiritual strategies
Number of subjects: 27
Study 21309844 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg daily
Number of subjects: 1973
Study 21309844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1973
Study 19166566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever having had a mammogram
Number of subjects: 537
Study 19166566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography use within the past 2 years
Number of subjects: 537
Study 16761235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin (0.3%) four times a day for 3 days
Number of subjects: 159
Study 16761235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 159
Study 16761235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin (0.3%)
Number of subjects: 159
Study 15101564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone i.m. 5 mg qid
Number of subjects: 306
Study 15101564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone i.m. 10 mg qid
Number of subjects: 306
Study 15101564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone i.m. 20 mg qid
Number of subjects: 306
Study 15101564 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol i.m. up to 10 mg bid-qid
Number of subjects: 306
Study 15101564 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to oral ziprasidone
Number of subjects: 306
Study 12269867 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL cases formatted in short segments
Number of subjects: 74
Study 12269867 — intervention group
Group type: COMPARATOR
Intervention: PBL cases formatted in long segments
Number of subjects: 74
Study 9845401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. for 2 weeks (RC)
Number of subjects: 350
Study 9845401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d., clarithromycin 500 mg b.d. and metronidazole 400 mg b.d. for 1 week (RCM)
Number of subjects: 350
Study 8136565 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA+azathioprine (Aza)+prednisone (TD)
Number of subjects: 92
Study 8136565 — intervention group
Group type: COMPARATOR
Intervention: Aza+prednisone (CsA D/C)
Number of subjects: 92
Study 2808259 — intervention group
Group type: EXPERIMENTAL
Intervention: More extensive treatment experimental group
Number of subjects: 96
Study 2808259 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment control group
Number of subjects: 96
Study 2808259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 1108582 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% with adrenaline 5 mug/ml
Number of subjects: 40
Study 1108582 — intervention group
Group type: COMPARATOR
Intervention: etidocaine 1.0% with adrenaline 5 mug/ml
Number of subjects: 40
Study 7358235 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary food
Number of subjects: 0
Study 7358235 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented mothers)
Number of subjects: 0
Study 31596897 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding information received by mothers
Number of subjects: 417
Study 31596897 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average household income per year
Number of subjects: 417
Study 29212350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ecological memory training
Number of subjects: 86
Study 29212350 — intervention group
Group type: EXPERIMENTAL
Intervention: High ecological memory training
Number of subjects: 86
Study 29212350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ecological reasoning training
Number of subjects: 86
Study 29212350 — intervention group
Group type: EXPERIMENTAL
Intervention: High ecological reasoning training
Number of subjects: 86
Study 29212350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 86
Study 26880476 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Climate Schools: Ecstasy and Emerging Drugs module delivered once weekly for 4 weeks during health education classes.
Number of subjects: 1126
Study 26880476 — intervention group
Group type: COMPARATOR
Intervention: Control group received health education as usual.
Number of subjects: 1126
Study 26880476 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Climate Schools: Ecstasy and Emerging Drugs module.
Number of subjects: 1126
Study 24699072 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary cART during primary HIV-infection
Number of subjects: 0
Study 22272935 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized health coaching (HC) intervention
Number of subjects: 220
Study 22272935 — intervention group
Group type: COMPARATOR
Intervention: Education Alone
Number of subjects: 220
Study 19758428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including individual motivational interviewing aimed at weight reduction, increase in physical activity, fibre and carbohydrate intake, and reduction of fat intake
Number of subjects: 102
Study 19758428 — intervention group
Group type: COMPARATOR
Intervention: Usual care Control
Number of subjects: 102
Study 18341810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker syndrome (PMS) group
Number of subjects: 48
Study 18341810 — intervention group
Group type: EXPERIMENTAL
Intervention: Without pacemaker syndrome (PMS) group
Number of subjects: 48
Study 18341810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 18341810 — intervention group
Group type: EXPERIMENTAL
Intervention: PMS group
Number of subjects: 48
Study 18341810 — intervention group
Group type: EXPERIMENTAL
Intervention: Without PMS group
Number of subjects: 48
Study 12847157 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine sufferers
Number of subjects: 45
Study 11783328 — intervention group
Group type: EXPERIMENTAL
Intervention: XMT plus western medicine
Number of subjects: 60
Study 11783328 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study 9195237 — intervention group
Group type: EXPERIMENTAL
Intervention: Side by side catheter
Number of subjects: 55
Study 9195237 — intervention group
Group type: COMPARATOR
Intervention: Coaxial catheter
Number of subjects: 55
Study 8482181 — intervention group
Group type: COMPARATOR
Intervention: Defecation upon urge
Number of subjects: 12
Study 8482181 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary suppression of defecation
Number of subjects: 12
Study 3514366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of tablets containing PGE2
Number of subjects: 345
Study 3514366 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous onset of labour
Number of subjects: 345
Study 31852811 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 (Arm A)
Number of subjects: 355
Study 31852811 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 with bevacizumab (Arm B)
Number of subjects: 355
Study 28319423 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 80 mg/d
Number of subjects: 0
Study 28319423 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 160 mg/d
Number of subjects: 0
Study 28319423 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 0
Study 28319423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25431431 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-FP-CIT SPECT scan (DaTSCAN™)
Number of subjects: 187
Study 25431431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scan)
Number of subjects: 187
Study 23676774 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) applied postoperatively for 5 days
Number of subjects: 26
Study 23676774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no KT application)
Number of subjects: 26
Study 21301812 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg hydrocortisone
Number of subjects: 48
Study 21301812 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 48
Study 21301812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19432828 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of exclusive breastfeeding
Number of subjects: 2094
Study 19432828 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic index (TI) at birth and at 8 weeks
Number of subjects: 2094
Study 19432828 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic size
Number of subjects: 2094
Study 17540227 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral inpatient treatment
Number of subjects: 267
Study 17540227 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic inpatient treatment
Number of subjects: 267
Study 17540227 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both types)
Number of subjects: 267
Study 15040538 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day of recombinant human growth hormone (rhGH) for 12 weeks
Number of subjects: 12
Study 15040538 — intervention group
Group type: COMPARATOR
Intervention: Placebo, alternate day or twice weekly dosing of rhGH
Number of subjects: 12
Study 11554425 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine combined with placebo for 21 days
Number of subjects: 0
Study 11554425 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine combined with mirtazapine for 7 days
Number of subjects: 0
Study 11554425 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine combined with placebo for 7 days
Number of subjects: 0
Study 11554425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine combined with carbamazepine for 21 days
Number of subjects: 0
Study 9385024 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 28
Study 7956582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anorectal procedures with lateral internal sphincterotomy
Number of subjects: 57
Study 7956582 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy alone (control group)
Number of subjects: 57
Study 3630804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine fading
Number of subjects: 28
Study 3630804 — intervention group
Group type: COMPARATOR
Intervention: Maintenance condition (includes behavioral contracting and extended treatment)
Number of subjects: 28
Study 3630804 — intervention group
Group type: COMPARATOR
Intervention: Maintenance condition
Number of subjects: 28
Study 31285069 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise program for 30 days, once a day for 7-10 minutes.
Number of subjects: 24
Study 31285069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 24
Study 31546969 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 22
Study 31546969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 28951402 — intervention group
Group type: EXPERIMENTAL
Intervention: Health equity-relevant randomised trials
Number of subjects: 0
Study 28951402 — intervention group
Group type: COMPARATOR
Intervention: Non-health equity relevant trials
Number of subjects: 0
Study 26169952 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time video consultation
Number of subjects: 31
Study 26169952 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-person consultation
Number of subjects: 31
Study 23419385 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine plus standard medical therapy (SMT)
Number of subjects: 60
Study 23419385 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus SMT
Number of subjects: 60
Study 23419385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of midodrine and clonidine plus SMT
Number of subjects: 60
Study 23419385 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 60
Study 23419385 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 60
Study 21627522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone IV (0.3 mg/kg)
Number of subjects: 8
Study 21627522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone OTM (0.6 mg/kg)
Number of subjects: 8
Study 19338551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sacral neuromodulation testing
Number of subjects: 20
Study 16772446 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea (GT)
Number of subjects: 20
Study 16772446 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Tea (BT)
Number of subjects: 20
Study 16772446 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-matched soda control (SC)
Number of subjects: 20
Study 15041578 — intervention group
Group type: COMPARATOR
Intervention: 0.8 mL/kg of plain local anesthetic mixture (lidocaine 1% + bupivacaine 0.25% (50/50) + 1 microg/mL of fentanyl)
Number of subjects: 48
Study 15041578 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/kg of the same mixture with 5 microg/mL of adrenaline
Number of subjects: 48
Study 11348933 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta(2)-agonist (SA), n = 48
Number of subjects: 145
Study 11348933 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta(2)-agonist (LA), n = 50
Number of subjects: 145
Study 11348933 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 47
Number of subjects: 145
Study 11348933 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SA, LA, Placebo)
Number of subjects: 145
Study 9554298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyproterone acetate lotion (20 mg)
Number of subjects: 40
Study 9554298 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 40
Study 9554298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyproterone acetate (2 mg) and ethinyl estradiol (0.035 mg)
Number of subjects: 40
Study 8061854 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 18
Study 8061854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 18
Study 8061854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 18
Study 8061854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18
Study 3197345 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (66 years and older) with aneurysmal SAH
Number of subjects: 61
Study 3197345 — intervention group
Group type: COMPARATOR
Intervention: Younger patients with aneurysmal SAH
Number of subjects: 61